Palm Angels inks fragrance licensing deal with Revlon
See catwalk
The new partnership with Revlon includes the development of fragrance lines for both men and women, as well as scented ancillary products. The first collection is expected to launch in 2027.
Founded in 2015 by Francesco Ragazzi, Palm Angels has been recognized for its unique blend of American skate culture and Italian craftsmanship, attracting a global fanbase that includes fashion insiders, musicians, and celebrities alike. Earlier this year, the Milanese brand was acquired by American firm Bluestar Alliance.
'We're thrilled to partner with Revlon to create Palm Angels' first permanent fragrance collection' said Joey Gabbay, CEO of Bluestar Alliance, which also recently acquired Off-White from LVMH.
'Revlon's expertise and capabilities will allow us to enter the fragrance business with confidence. Palm Angels has always aimed to create a lifestyle experience for our customers rooted in street culture that extends beyond clothing, and fragrance is a natural next step to shaping this world upon the brand's 10-year anniversary."
The deal is also set to bolster Revlon's fragrance brand portfolio, as it enters its next phase of growth.
'This partnership with one of Europe's most exciting fashion brands is both transformative and full of potential for Revlon," said Michelle Peluso, CEO of Revlon.
"As we focus on accelerating Revlon's fragrance business, Palm Angels is a fantastic partner who will help us reach new, prestige audiences, in new geographies and across new distribution channels. The Palm Angels team has built a highly engaged following and together I look forward to serving them further through this landmark fragrance deal.'
Earlier this month, the New York-based company announced a new global fragrance licensing deal with four-time Grammy-nominated artist, Ice Spice.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
16 minutes ago
- Euronews
Trump warns EU: 35% tariffs if $600bn investment pledge unfulfilled
A controversial investment pledge forming part of the EU-US trade deal will need to be honoured by the EU or 35% blanket tariffs will be applied to the bloc, US President Donald Trump has warned. On Tuesday President Trump was quizzed on the deal he agreed by handshake with Commission President Ursula von der Leyen in Scotland on 27 July on CNBC's 'Squawk Box' via phone. He touted the US position - which a White House fact sheet stated - that the agreement included a pledge for the EU to invest $600 billion in the US by the end of his second term. "This new investment is in addition to the over $100 billion (that) EU companies already invest in the United States every year," the fact sheet stated following the deal. The European Commission is unable to design and implement investments on behalf of the private sector. The $600 billion has been described by the Commission as an indication based on the executive's contacts with industry. "It's not something the EU, as a public authority, can guarantee – it's something based on the intention of private companies," a senior official said last week. Asked on Squawk Box what teeth there were in the investment pledge element of the deal, Trump said, if it didn't happen, 'then they pay tariffs of 35%'. Trump said that the investment pledge was one of the reasons he had dropped tariffs to a blanket 15% rate, so if it is unfulfilled then higher tariffs will click back in. The EU has been approached for comment. The Commission on Tuesday suspended a package of trade countermeasures targeting €93 billions' worth of American goods which was scheduled to take effect on 7 August, as it continues to negotiate a joint statement formalising the agreement struck by von der Leyen and Trump in Scotland.
Fashion Network
an hour ago
- Fashion Network
India accuses EU, US of double standard over Russian trade
India has sharply criticised the US and the European Union, saying it is being unfairly singled out by them over its Russian oil purchases when they both trade extensively with Moscow despite the war in Ukraine. India's criticism followed a renewed threat by US President Donald Trump on Monday to raise tariffs on goods from India over its Russian oil purchases, deepening the trade rift between the two countries. In a rare show of unity, Prime Minister Narendra Modi's Bharatiya Janata Party (BJP) and the main opposition Congress on Tuesday condemned Trump's repeated criticism of New Delhi. India's Foreign Ministry said in a statement issued late on Monday that "it is revealing that the very nations criticising India are themselves indulging in trade with Russia". The US embassy and the EU's delegation in New Delhi did not immediately respond to a request for comment. Both the US and EU have sharply scaled back their trade ties with Russia since it launched a full-scale invasion of Ukraine in February 2022. In 2021, Russia was the EU's fifth-largest trading partner, with goods exchange worth 258 billion euros, according to the EU executive European Commission. The sudden rift between India and the US has been deepening since July 31, when Trump announced a 25% tariff on Indian goods being shipped to the US and for the first time threatened unspecified penalties for buying Russian oil. India is one of the biggest buyers of crude from Russia, importing about 1.75 million barrels per day from January to June this year, up 1% from a year ago. India has said it does not support "unilateral sanctions" by the EU. Trade experts say Trump's tariff could badly hurt India's economy. Ajay Srivastava of the New Delhi-based Global Trade Research Initiative said he expected Indian goods exports to the US to fall 30% in the current fiscal year ending March 31, to 60.6 billion dollars from 86.5 billion dollars in the 2025 fiscal year. India's equity benchmarks fell after Trump's renewed threat of harsh tariffs on goods from India. Manish Tewari, a member of parliament and Congress leader, said Trump's "disparaging remarks hurt the dignity and self-respect of Indians". "The time has come to call out this constant bullying and hectoring," he added. BJP Vice President Baijayant Jay Panda quoted Henry Kissinger - the most powerful US diplomat of the Cold War era - in a post on X: "To be an enemy of America can be dangerous, but to be a friend is fatal."
Euronews
2 hours ago
- Euronews
Pfizer earnings strong despite Trump's new 'up to 250%' tariff threat
Pharmaceutical giant Pfizer reported better-than-expected quarterly results on Tuesday and improved its predictions for full-year profits, beating Wall Street expectations. The New York-based company reported second-quarter sales of $14.7 billion (€12.74bn) and earnings per share of $0.51 (€0.44). As of around 16.00 CEST, Pfizer shares were up over 4% at $24.58. "Our business is performing well and I'm pleased with the progress we achieved in the second quarter," chairman and CEO Albert Bourla said in a statement. "We continue to be actively engaged with policymakers as we navigate a complicated and rapidly evolving geopolitical environment while also remaining focused on advancing our business," Bourla continued. This despite several policies announced by the current US administration that could hurt drugmakers. In May, US President Donald Trump signed an executive order whereby pharmaceutical companies would be compelled to lower prices based on a "Most Favored Nation" policy. The price-slashing scheme seeks to ban drug companies from selling products in the US at prices above those in other developed countries. In Europe, the comparison becomes complex, as a significant portion pharmaceutical costs are covered by national healthcare or insurance systems, lowering prices for consumers. Experts warned at the time that this could slash their US revenues and affect availability. Even so, the president doubled down on his plans, sending letters last week to 17 drugmakers, calling for concrete steps to cut prices by 29 September. That includes agreeing to provide their full portfolio of existing medicines at no higher than European prices to every single Medicaid patient. On Tuesday, in an interview with CNBC, he announced that tariffs for pharmaceuticals and semiconductors would be coming in "next week". 'We'll be putting an initially small tariff on pharmaceuticals, but in one year, one-and-a-half years, maximum, it's going to go to 150% and then it's going to go to 250% because we want pharmaceuticals made in our country," he told CNBC.
